NCM USA BRONX LLC is a generic drug manufacturer focused on Oncology, Neurology.
NCM USA BRONX LLC's Key Drugs
NCM USA BRONX LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NCM USA BRONX LLC's Recent FDA Approvals
New NDA/BLA approvals for NCM USA BRONX LLC over the last two years — novel drugs only, excluding generics and label supplements.
NCM USA BRONX LLC's Therapeutic Areas
NCM USA BRONX LLC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NCM USA BRONX LLC's Top Competitors
NCM USA BRONX LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NCM USA BRONX LLC Pipeline Snapshot
Active clinical trials for NCM USA BRONX LLC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2014-11-28
- Latest
- 2015-02-04
- Applications
- 3